4D Molecular Therapeutics reported Q3 2025 results with significant progress in strategic partnerships and clinical development, notably the Otsuka collaboration for 4D-150 and positive long-term data for 4D-150 in wet AMD. The company strengthened its balance sheet through an equity offering and secured investment from the Cystic Fibrosis Foundation, extending its cash runway into the second half of 2028.
Entered strategic partnership with Otsuka Pharmaceutical for 4D-150 in APAC, receiving $85M upfront and expecting at least $50M in cost sharing.
positiveAnnounced positive long-term safety and efficacy data for 4D-150 in wet AMD with 1.5 to 2 years of follow-up.
positiveCompleted equity offering with net proceeds of ~$93 million, strengthening the balance sheet.
positiveSecured up to $11 million equity investment from the Cystic Fibrosis Foundation to accelerate 4D-710 development.
positiveCash runway extended into the second half of 2028, sufficient beyond primary readouts for 4D-150 Phase 3 trials.
positiveNet loss increased to $56.9 million in Q3 2025 from $43.8 million in Q3 2024, primarily due to increased R&D expenses.
negativeResearch and development expenses increased by 28.4% YoY to $49.4 million, driven by Phase 3 clinical trials for 4D-150.
attentionMargin metrics will be available once backend extracts data from insights_json
Meaningful progress building upon and validating our business strategy focusing on 4D-150 and 4D-710.
Partnership with Otsuka, new data on 4D-150, equity investment from CF Foundation, and strengthened balance sheet position us well.
Cash runway into 2H 2028 beyond primary readout for 4D-150 4FRONT Phase 3 trials and provides for indication expansion in diabetic macular edema.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.